First-line and particularly second-line metastatic CRC have become very crowded treatment settings, with multiple combinations of chemotherapies and targeted agents competing for the same patient subsets. 

Bevacizumab, the first targeted agent launched in the indication, is the traditional standard of care and remains widely prescribed in both first-line and second-line disease and across tumor profiles. However, the branded drug (Avastin) is approaching the end of its lifecycle, and with several bevacizumab biosimilars already launched, its market share will continue to decrease. Nevertheless, bevacizumab’s potential incorporation into new, highly active combination therapies in first-line and third-line mCRC stands to cement the drug’s status as a standard of care. 

This Datamonitor Healthcare report contains a Disease Analysis module.